Questran
(Cholestyramine)ApprovedSmall molecule
Cholestyramine is used to lower cholesterol levels in the blood and can also help relieve itching caused by certain liver conditions. It works by binding to cholesterol in your digestive system so your body removes it instead of absorbing it.[2] Questran is currently approved and in use across 14 indications[4].[1]
Questran is one of 296 small molecule programs targeting Multiple Sclerosis. It is currently in Approved.
14
Indications
23
Total Trials
5
Active Trials
295
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 13 indications
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Byetta
AstraZenecaPreclinical
Medrol
PfizerPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
Hyperpolarized 13c Pyruvate
UUniversity of Maryland, Baltimore
Preclinical
PEG-Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Hyperthyroidism2 trials
Efficacy and Safety of Cholestyramine and Prednisolone as Adjunctive Therapy in Treatment of Overt Hyperthyroidism
Unknown status·—·Phase 3·NCT03303053·135 enrolled
Familial Hypercholesterolemia2 trials
Multiple Sclerosis2 trials
Acceptability2 trials
14 more indications
Renal Impairment1 trial
Female1 trial
Exploratory Evaluation of the Effect of Cholestyramine on Serum Levels of POPs in Obese Female Patients
Recruiting·—·N/A·NCT05966727·20 enrolled
Short Bowel Syndrome1 trial
Hyperlipidemia1 trial
Pancreatic Cancer1 trial
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
Recruiting·—·Phase 1·NCT06454383·19 enrolled
Homozygous Familial Hypercholesterolemia1 trial
Multiple Myeloma1 trial
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
Active, not recruiting·—·Phase 2·NCT05014646·27 enrolled
Regulatory
FDA Approval Timeline[5]
Jan 1, 1982
QUESTRAN
NDA NDA016640
Dec 5, 1988
QUESTRAN LIGHT
NDA NDA019669
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Questran drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Cholestyramine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details